C4 Therapeutics, Inc. (CCCC) - Q3 2025 10-Q Summary
Business Context and Reporting Period
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing targeted protein degradation (TPD) medicines using its proprietary TORPEDO platform. The company focuses on oncology indications, with its lead candidate, cemsidomide, in Phase 1 trials for multiple myeloma and non-Hodgkin lymphoma. This report covers the quarterly period ended September 30, 2025.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | YTD 9M 2025 | YTD 9M 2024 |
|---|---|---|---|---|
| Revenue | $11.2 million | $15.4 million | $24.9 million | $30.4 million |
| Net Loss | $(32.2) million | $(24.7) million | $(84.5) million | $(70.7) million |
| Loss Per Share (Basic/Diluted) | $(0.44) | $(0.35) | $(1.18) | $(1.03) |
| Cash & Cash Equivalents | $58.8 million | $59.6 million | $58.8 million | $59.6 million |
| Marketable Securities | $141.0 million | $211.8 million | $141.0 million | $211.8 million |
| Total Liquidity (Cash + Securities) | $199.8 million | $271.4 million | $199.8 million | $271.4 million |
| Operating Cash Flow (9M) | $(76.5) million | $(47.2) million | $(76.5) million | $(47.2) million |
Note: The company has no product sales revenue; all revenue is derived from collaboration agreements.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 27% in Q3 2025 compared to Q3 2024. This was primarily driven by a $6.0 million decrease in Biogen collaboration revenue (due to milestone timing) and a $2.9 million decrease in Betta Pharma revenue. These decreases were partially offset by increases in Merck and Roche collaboration revenue.
- Impairment Charge: The company recognized a one-time $10.7 million impairment charge in Q3 2025 related to long-lived assets. This resulted from entering a new sublease agreement that triggered an impairment analysis of the right-of-use asset and leasehold improvements.
- Expense Management: Research and development (R&D) expenses decreased by $5.8 million in Q3 2025 compared to the prior year, driven by lower preclinical development costs and the completion of the Phase 1 trial for CFT1946. General and administrative (G&A) expenses also decreased by $2.8 million, largely due to reduced stock-based compensation.
- Collaboration Updates:
- Merck: Received notice of termination of the Merck Agreement in September 2025, effective late November 2025. The company recognized the remaining deferred revenue upon notice.
- Pfizer: Entered a new Clinical Trial Collaboration and Supply Agreement to supply elranatamab for a Phase 1b trial of cemsidomide.
- Biogen: Earned a $2.0 million milestone in September 2025 for advancing BIIB142 into the clinic.
Guidance, Outlook, and Risks
- Capital Raise (Subsequent Event): In October 2025, the company completed an underwritten offering of common stock, pre-funded warrants, and Class A/B warrants. The company received net proceeds of approximately $117.0 million. If all warrants are exercised, total gross proceeds could reach $341.7 million.
- Liquidity Runway: Management believes that existing cash, cash equivalents, marketable securities, and the proceeds from the October 2025 offering will be sufficient to fund operations through the end of 2028.
- Development Outlook: The company plans to initiate a Phase 1b trial of cemsidomide in combination with elranatamab in 2026 and a registrational Phase 2 trial. The company decided not to advance CFT1946 beyond Phase 1.
- Risks:
- Profitability: The company has incurred significant losses since inception and expects to continue incurring losses for the foreseeable future.
- Warrant Exercise Uncertainty: The company may not receive additional funds from the Class A and B warrants issued in the October 2025 offering if the stock price does not exceed the exercise price ($2.22) before expiration.
- Regulatory & Clinical: Risks include the failure of clinical trials to demonstrate safety/efficacy, delays in regulatory approval, and the unproven nature of the TORPEDO platform.
Investor Verification Checklist
- Warrant Economics: Verify the likelihood of the Class A and Class B warrants being exercised given the current stock price relative to the $2.22 exercise price and the specific expiration triggers (e.g., data release for Class A).
- Merck Termination Impact: Confirm the final accounting treatment of the Merck agreement termination and ensure no further contingent liabilities or revenue recognition issues remain.
- Impairment Details: Review the specific assumptions used in the $10.7 million impairment calculation regarding the sublease and right-of-use assets to assess future lease cost implications.
- Cash Burn Rate: Monitor the quarterly cash burn rate against the projected runway to end of 2028, considering the new capital raised in October 2025.
- Clinical Milestones: Track the initiation timeline for the cemsidomide Phase 1b trial with Pfizer and the Phase 2 registrational trial, as these are critical for future valuation.